Comparison of immediate-release and controlled release carbidopa/levodopa in parkinson’s disease

European Neurology

Volumn 37, Issue 1, 1997, Pages 23-27

  Block, Gilbert ^a   Liss, Charles ^a   Reines, Scott ^a   Irr, Joseph ^b   Nibbelink, Donald ^b   Aarli, Johan ^c   Aguilar, M ^c   Ahrens, Suzanne ^c   Bakheit, A ^d   Baumel, Barry ^c   Bertoni, John ^c   Capildeo, Rudy ^e   Castro Caldas, Alexandre ^c   Deza, Luis ^c   Donaldson, Ivan ^c   Franck, Georges ^c   Fusillo, Jose ^c   Gauthier, Serge ^c   Gershanik, Oscar ^f   Granerus, Ann Katherine ^g   Hauser, Robert A ^c   Hennessey, Keven ^c   Hutton, J Thomas ^c   Joffe, Ronald ^c   Koller, William ^c   Last, Barbara ^c   LeWitt, Peter ^h   Mamoli, Bruno ^c   Manyam, Bala ^c   Mark, Margery ^c   Nakano, Kenneth ^c   Nausieda, Paul ^c   Otero, Enrique ⁱ   Paulson, George ^c   Pinter, Michaela ^c   Reich, Stephen ^c   Rodnitzky, Robert ^c   Sage, Jacob ^c   Sampaio, Cristina ^c   Smith, Betty ^c   Teräväinen, Heikki ^c   Tetrud, James ^c   Tolosa, Eduardo ^c   Ulm, Gudrun ^c   Valesco, Francisco ⁱ   more..

^a MERCK RESEARCH LABORATORIES   (United States)

^b DUPONT COMPANY   (United States)

^c NONE   (Germany)

^d Glasgow   (United Kingdom)

^e NONE   (United Kingdom)

^f NONE   (Argentina)

^g NONE   (Sweden)

^h NONE   (United States)

ⁱ Lab of Comparative Neurophysiology   (Mexico)

Author keywords

5 year study; Activities of daily living; Nottingham Health Profile; Parkinson s disease; Sinemet; Sinemet CR; UPDRS

Indexed keywords

CARBIDOPA PLUS LEVODOPA;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DEPRESSION; DRUG BLOOD LEVEL; DYSKINESIA; FEMALE; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; PARKINSON DISEASE; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; VERTIGO;

ACTIVITIES OF DAILY LIVING; AGED; ANTIPARKINSON AGENTS; CARBIDOPA; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FEMALE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; NEUROLOGIC EXAMINATION; PARKINSON DISEASE;

EID: 8044229410     PISSN: 00143022     EISSN: 14219913     Source Type: Journal    
DOI: 10.1159/000117399     Document Type: Article

References (17)

1. Koller WC, Hubble JP: Levodopa therapy in Parkinson's disease. Neurology 1990:40(suppl 3):40-47.
2. Marsden CD, Parkes JD: Success and problems of long-term levodopa therapy in Parkinson's disease. Lancet 1977;i:345-349.
3. Poewe WH, Lees AJ, Stem GM, Loxy-dose L-dopa therapy in Parkinson’s disease: A 6-ycar follow-up study. Neurology 1986:36:1528-1530.
4. Marsden CD, Parkes JD, Quinn N: Fluctuations of disability in Parkinson’s disease; clinical aspects: in Marsden CD. Fahn S (eds): Movement Disorders. London. Butterworths. 1982. pp 96-122.
5. Nutt JG, Woodward WR: Levodopa pharmacokinetics and pharmacodynamics in fluctuating parkinsonian patients. Neurology 1986:36: 739-744.
6. Juncos JL, Engber TM, Raisman R, et al: Continuous and intermittent levodopa differentially affect basal ganglia function. Ann Neurol 1989:25:473-478.
7. 2-dopamine agonists. EurJ Pharmacol 1989:168:291-298.
8. Alba A, Trainor FS, Ritter W, Dasco MM: A clinical disability rating for Parkinson’s patients. J Chron Dis 1968:21:507-522.
9. Canter CJ, de la Torre R, Mier M: A method of evaluating disability in patients with Parkinson’s disease. J Nerv Meni Dis 1961:133:143-147.
10. Fahn S, Eton RL, and members of the UPDRS Development Committee: Unified Parkinson’s disease rating scale: in Fahn S, Marsden CD, Goldstein M. et al (eds): Recent Developments in Parkinson's disease, part II. Florham Park, MacMillan Healthcare Information, 1987.
11. Hoehn MM, Yahr MD: Parkinsonism: Onset, progression and mortality. Neurology 1967; 17: 427-442.
12. Sehwab RS, England AC: Projection technique for evaluating surgery in Parkinson’s disease: in Gillingham FJ. Donaldson IML (eds): Third Symposium on Parkinson’s disease. Edinburgh. Livingstone, 1969, pp 152-157.
13. Hunt SM, McKenna SP, McEwen J, Backett EM, Williams J, Papp E: A quantitative approach to perceived health status: A validation study. J Epidemiol Comm Health 1980;34: 281-286.
14. DuPont E, Anderson A, Bors J, et al: Sustained-release Madopar HBS® compared to standard Madopar® in the long-term treatment of de novo parkinsonian patients. Acta Neurol Scand 1996;93:14-20.
15. Chase TN, Engber TM, Mouradian MM: Palla-tive and prophylactic benefits of continuously administered dopamimeties in Parkinson's disease. Neurology 1994;44(suppl 6):515-518.
16. Chase TN, Mouradian MM, Engber TM: Motor response complications and the function of striatal afferent systems. Neurology 1993; 43(suppl 6):523-527.
17. Rinne UK, Rinne OG: Madopar® MBS® in the treatment of early Parkinson’s disease: in Agroli A, Campanella C (eds): New Developments in the T rcatment of Parkinson’s Disease. Rome. Libbey, 1991, pp 17-21.